Housing First for homeless people with severe mental illness: extended 4-year follow-up and analysis of recovery and housing stability from the randomized


Journal

Epidemiology and psychiatric sciences
ISSN: 2045-7979
Titre abrégé: Epidemiol Psychiatr Sci
Pays: England
ID NLM: 101561091

Informations de publication

Date de publication:
07 Feb 2022
Historique:
entrez: 7 2 2022
pubmed: 8 2 2022
medline: 9 2 2022
Statut: epublish

Résumé

Housing First (HF), a recovery-oriented approach, was proven effective in stabilising housing situations of homeless individuals with severe mental disorders, yet had limited effectiveness on recovery outcomes on a short-term basis compared to standard treatment. The objective was to assess the effects of the HF model among homeless people with high support needs for mental and physical health services on recovery, housing stability, quality of life, health care use, mental symptoms and addiction issues on 4 years of data from the Un Chez Soi d'Abord trial. A multicentre randomised controlled trial was conducted from August 2011 to April 2018 with intent-to-treat analysis in four French cities: Lille, Marseille, Paris and Toulouse. Participants were homeless or precariously-housed patients with a DSM-IV-TR diagnosis of bipolar disorder or schizophrenia. Two groups were compared: the HF group (n = 353) had immediate access to independent housing and support from the assertive community treatment team; the Treatment-As-Usual (TAU) group (n = 350) had access to existing support and services. Main outcomes were personal recovery (Recovery Assessment Scale (RAS) scale), housing stability, quality of life (S-QoL), global physical and mental status (Medical Outcomes Study 36-item Short Form Health Survey (SF-36)), inpatient days, mental symptoms (Modified Colorado Symptom Index (MCSI)) and addictions (Mini International Neuropsychiatric Interview (MINI) and Alcohol Use Disorders Identification Test (AUDIT)). Mixed models using longitudinal and cluster designs were performed and adjusted to first age on the street, gender and mental disorder diagnosis. Models were tested for time × group and site × time interactions. The 703 participants [123 (18%) female] had a mean age of 39 years (95% CI 38.0-39.5 years). Both groups improved RAS index from baseline to 48 months, with no statistically significant changes found between the HF and TAU groups over time. HF patients exhibited better autonomy (adjusted β = 2.6, 95% CI 1.2-4.1) and sentimental life (2.3, 95% CI 0.5-4.1), higher housing stability (28.6, 95% CI 25.1-32.1), lower inpatient days (-3.14, 95% CI -5.2 to -1.1) and improved SF-36 mental composite score (-0.8, 95% CI -1.6 to -0.1) over the 4-year follow-up. HF participants experienced higher alcohol consumption between baseline and 48 months. No significant differences were observed for self-reported mental symptoms or substance dependence. Data at 4 years were consistent with 2-year follow-up data: similar improvement in personal recovery outcomes but higher housing stability, autonomy and lower use of hospital services in the HF group compared to the TAU group, with the exception of an ongoing alcohol issue. These sustained benefits support HF as a valuable intervention for the homeless patients with severe mental illness. ClinicalTrials.gov identifier: NCT01570712.

Identifiants

pubmed: 35125129
doi: 10.1017/S2045796022000026
pii: S2045796022000026
pmc: PMC8851060
doi:

Banques de données

ClinicalTrials.gov
['NCT01570712']

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

e14

Subventions

Organisme : Direction Générale de l'offre de Soins Direction Générale de l'offre de Soins Janssen Pharmaceutical Company

Références

JAMA. 2017 Feb 21;317(7):695-696
pubmed: 28241364
Can J Psychiatry. 2007 Dec;52(12):798-802
pubmed: 18186180
Epidemiol Psychiatr Sci. 2020 Sep 30;29:e169
pubmed: 32996442
Psychiatr Serv. 2013 Oct;64(10):974-80
pubmed: 23820592
Addiction. 2015 Oct;110(10):1615-6
pubmed: 26350712
Drug Alcohol Depend. 2015 Jan 1;146:24-9
pubmed: 25465295
Lancet Public Health. 2020 Jun;5(6):e342-e360
pubmed: 32504587
Community Ment Health J. 2014 May;50(4):466-73
pubmed: 24337472
Schizophr Bull. 2004;30(4):1035-41
pubmed: 15957202
J Prim Prev. 2007 Jul;28(3-4):265-79
pubmed: 17592778
J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57
pubmed: 9881538
Health Res Policy Syst. 2018 Apr 19;16(1):34
pubmed: 29673362
Int J Environ Res Public Health. 2018 Mar 14;15(3):
pubmed: 29538346
Med Decis Making. 2015 Apr;35(3):388-97
pubmed: 25398623
Am J Psychiatry. 2006 Jan;163(1):148-50
pubmed: 16390903
Psychol Serv. 2010;7(4):219-232
pubmed: 21829324
Psychiatr Serv. 2014 Apr 1;65(4):442-53
pubmed: 24487405
J Epidemiol Community Health. 2019 May;73(5):379-387
pubmed: 30777888
Am J Community Psychol. 2008 Dec;42(3-4):251-65
pubmed: 18956238
BMC Health Serv Res. 2010 Jun 11;10:161
pubmed: 20540771
Health Soc Care Community. 2008 Jan;16(1):1-15
pubmed: 18181811
Br J Psychiatry. 1999 Apr;174:346-52
pubmed: 10533554
Multivariate Behav Res. 2016 Jul-Aug;51(4):495-518
pubmed: 27269278
Trials. 2013 Sep 24;14:309
pubmed: 24063556
J Clin Epidemiol. 2014 Mar;67(3):267-77
pubmed: 24275499
Psychiatr Serv. 2010 Mar;61(3):293-9
pubmed: 20194407
Schizophr Bull. 2006 Jul;32(3):432-42
pubmed: 16461575
Rev Epidemiol Sante Publique. 1995;43(4):371-9
pubmed: 7667543
Psychiatr Rehabil J. 2007 Summer;31(1):23-31
pubmed: 17694712
Asian J Psychiatr. 2015 Apr;14:13-8
pubmed: 25703654
Schizophr Res. 2015 Dec;169(1-3):234-240
pubmed: 26431792
J Psychiatr Pract. 2008 May;14 Suppl 2:45-54
pubmed: 18677199
Health Serv Res. 2016 Feb;51(1):282-301
pubmed: 26119335
Community Ment Health J. 1994 Aug;30(4):363-83
pubmed: 7956112
J Ment Health. 2015 Apr;24(2):103-10
pubmed: 25643043
Schizophr Bull. 2018 Apr 6;44(3):631-642
pubmed: 29036720
Psychiatr Serv. 2014 Jun 1;65(6):739-50
pubmed: 24535245
Lancet Psychiatry. 2019 Nov;6(11):915-925
pubmed: 31601530
JAMA. 2015 Mar 3;313(9):905-15
pubmed: 25734732
Community Ment Health J. 2011 Apr;47(2):227-32
pubmed: 20063061
World Psychiatry. 2020 Feb;19(1):40-50
pubmed: 31922678
Am J Psychiatry. 2004 Mar;161(3):473-9
pubmed: 14992973
J Clin Psychol. 2021 Jun;77(6):1472-1486
pubmed: 33188711
Psychiatr Rehabil J. 2019 Jun;42(2):169-181
pubmed: 30843721
Am J Public Health. 2013 Dec;103 Suppl 2:S269-74
pubmed: 24148063
Psychiatr Serv. 2016 Mar;67(3):275-81
pubmed: 26620289
Arch Phys Med Rehabil. 2007 Apr;88(4):529-36
pubmed: 17398257
Schizophr Res. 2015 Dec;169(1-3):292-297
pubmed: 26522850
J Dual Diagn. 2017 Jul-Sep;13(3):219-229
pubmed: 28414579
Psychiatr Serv. 2011 Feb;62(2):171-8
pubmed: 21285095
Psychiatr Serv. 2000 Apr;51(4):487-93
pubmed: 10737824
BMC Psychiatry. 2017 Feb 17;17(1):72
pubmed: 28212630
BMC Psychiatry. 2016 Feb 25;16:41
pubmed: 26912081
Subst Abus. 2018;39(4):497-504
pubmed: 29595364
Ment Health Serv Res. 2001 Sep;3(3):141-53
pubmed: 11718206
Qual Health Res. 2019 Jul;29(9):1313-1323
pubmed: 30499369
Milbank Q. 2009 Jun;87(2):495-534
pubmed: 19523126
Am J Public Health. 2004 Apr;94(4):651-6
pubmed: 15054020
Schizophr Res. 2010 Aug;121(1-3):241-50
pubmed: 20541912
Expert Rev Neurother. 2020 Feb;20(2):123-125
pubmed: 31906736
Br J Addict. 1992 Oct;87(10):1415-31
pubmed: 1330126

Auteurs

S Loubière (S)

School of Medicine - La Timone Medical Campus, Aix-Marseille University, UR 3279: CEReSS - Health Service Research and Quality of Life Center, 13005Marseille, France.
Department of Clinical Research and Innovation, Epidemiology and Economic Evaluation Unit, Assistance Publique - Hôpitaux de Marseille, APHM, 13005Marseille, France.

C Lemoine (C)

School of Medicine - La Timone Medical Campus, Aix-Marseille University, UR 3279: CEReSS - Health Service Research and Quality of Life Center, 13005Marseille, France.
Department of Clinical Research and Innovation, Epidemiology and Economic Evaluation Unit, Assistance Publique - Hôpitaux de Marseille, APHM, 13005Marseille, France.

M Boucekine (M)

School of Medicine - La Timone Medical Campus, Aix-Marseille University, UR 3279: CEReSS - Health Service Research and Quality of Life Center, 13005Marseille, France.
Department of Clinical Research and Innovation, Epidemiology and Economic Evaluation Unit, Assistance Publique - Hôpitaux de Marseille, APHM, 13005Marseille, France.

L Boyer (L)

School of Medicine - La Timone Medical Campus, Aix-Marseille University, UR 3279: CEReSS - Health Service Research and Quality of Life Center, 13005Marseille, France.
Department of Medical Information, Assistance Publique - Hôpitaux de Marseille, APHM, 13005Marseille, France.

V Girard (V)

School of Medicine - La Timone Medical Campus, Aix-Marseille University, UR 3279: CEReSS - Health Service Research and Quality of Life Center, 13005Marseille, France.

A Tinland (A)

School of Medicine - La Timone Medical Campus, Aix-Marseille University, UR 3279: CEReSS - Health Service Research and Quality of Life Center, 13005Marseille, France.
Department of Psychiatry, APHM - University Hospital, 13009Marseille, France.

P Auquier (P)

School of Medicine - La Timone Medical Campus, Aix-Marseille University, UR 3279: CEReSS - Health Service Research and Quality of Life Center, 13005Marseille, France.
Department of Clinical Research and Innovation, Epidemiology and Economic Evaluation Unit, Assistance Publique - Hôpitaux de Marseille, APHM, 13005Marseille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH